Roche's Faricimab has been a success in the study of diabetic macular edema

Roche recently announced that its research-specific antibody Faricimab has reached its main endpoint in two Phase III studies of diabetic macular edema (DME).
diabetic retinal lesions are a serious blinding eye disease, diabetic macular edema can occur at any time of diabetic retinal lesions, often causing irreversible vision loss.
Faricimab targets two pathways involving vision loss - angiogen 2 (Ang-2) and angio endothorkin growth factor A (VEGF-A).
these pathways drive vision loss by making blood vessels unstable, which leads to the formation of new leaking blood vessels and increases inflammation.
results suggest that Faricimab has the potential to provide long-lasting vision improvements for patients with diabetic macular edema, while also reducing the burden of treatment associated with frequent injections, Roche said.
we look forward to discussions with regulators around the world with a view to bringing this potential new treatment to DME patients as soon as possible.